Zsolt Lavotha has been appointed acting CEO of Swedish Biomimetics 3000® Ltd

Zsolt Lavotha has been appointed acting CEO of Swedish Biomimetics 3000® Ltd (SB3000 Ltd), a pioneer in green, continuous manufacturing of pharmaceutical products.

Zsolt has extensive experience in healthcare in both large pharma and biotech including senior global positions in Wyeth and Pfizer, CEO of Orexo and Lavipharm.  Zsolt will be taking day to day control of the technical teams who are based in Norfolk UK, Lund Sweden and Copenhagen Denmark and will lead the ongoing partnership programmes with a variety of organisations including major pharma and contract manufacturers.

This follows the resignation of Andreas Segerros, who is joining a life sciences focused venture fund.  A search for a new CEO has been initiated.

About Swedish Biomimetics 3000® Ltd (SB3000 Ltd)

SB3000 Ltd was founded by Lars-Uno Larsson; serial entrepreneur and recipient of The Honoree Award for Visionary and Pioneering Guidance in the Orphan Drug area.  Over the last few years SB3000 Ltd has developed a ground breaking solid phase continuous manufacturing synthesis solution, named µLOT®, aimed at replacing the expensive and environmentally damaging batch processing, which currently is being widely used in manufacturing medicinal products.  The Company is initially focusing on the continuous manufacture of peptides, as the present batch process is highly toxic, expensive, can be of variable quality and is inflexible.

For further information please contact:

Lars-Uno Larsson at:  larsuno.larsson@swedishbiomimetics3000.com

Zsolt Lavotha at:  z.lavotha@sb3000.tech